| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Nadolol D9 targets β-adrenergic receptors, specifically acting as a non-selective β-blocker. As a labeled analogue, it retains the same pharmacological properties as the parent compound and is used as a tracer in pharmacokinetic and bioanalytical studies. It blocks the effects of catecholamines on β-receptors, reducing heart rate and blood pressure.
|
|---|---|
| ln Vitro |
In vitro activity of Nadolol D9 is not typically assessed separately from the parent compound, as it is primarily used as an analytical standard. The deuterium labeling does not significantly alter the compound's pharmacological activity, and its β-blocking effects are expected to be identical to those of unlabeled nadolol.
|
| ln Vivo |
In vivo activity of Nadolol D9 mirrors that of nadolol, which is a clinically effective non-selective β-blocker used for hypertension and angina. The deuterated analogue is used in pharmacokinetic studies to track the disposition of nadolol in vivo. Its pharmacological effects are mediated through β-adrenergic receptor blockade.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Nadolol D9 are not typically performed, as the compound is used as an analytical standard rather than as a pharmacological tool. For the parent compound nadolol, receptor binding assays involve measuring β-adrenergic receptor affinity using radioligand binding techniques. The deuterated analogue would be expected to show identical binding properties.
|
| Cell Assay |
In vitro cellular assays for Nadolol D9 are not typically performed, as the compound is used as an internal standard for LC-MS analysis. The parent compound nadolol is studied in cell-based assays to assess β-adrenergic receptor blockade. The deuterated analogue serves as a reference for quantifying nadolol concentrations in cellular samples.
|
| Animal Protocol |
In vivo animal experiments for Nadolol D9 are typically conducted as part of pharmacokinetic studies. The compound is administered to animals, and blood or tissue samples are collected at various time points. The deuterated compound is used as an internal standard for the quantification of nadolol levels by LC-MS, enabling accurate measurement of drug concentrations and pharmacokinetic parameters.
|
| ADME/Pharmacokinetics |
Nadolol D9 is used as an internal standard for the quantification of nadolol in pharmacokinetic studies by mass spectrometry. The deuterium labeling provides a mass shift that allows the labeled and unlabeled compounds to be distinguished during analysis. The compound has a molecular weight of 318.46 and molecular formula C₁₇H₁₈D₉NO₄. It should be stored appropriately.
|
| Toxicity/Toxicokinetics |
Toxicological data for Nadolol D9 are not separately reported, as it is a labeled analogue of nadolol. The safety profile of nadolol is well established from clinical use, with common adverse effects including bradycardia, fatigue, and dizziness. The deuterated analogue is used in research applications at very low concentrations as an analytical standard, posing minimal toxicity risk.
|
| References | |
| Additional Infomation |
Nadolol D9 is a deuterium-labeled analogue of nadolol with CAS number 94513-92-5, molecular formula C₁₇H₁₈D₉NO₄, and molecular weight 318.46. It is used as an internal standard for the quantification of nadolol in biological samples by LC-MS. Nadolol is a non-selective β-adrenergic receptor blocker. This product is for research use only.
|
| Molecular Formula |
C17H18D9NO4
|
|---|---|
| Molecular Weight |
318.456
|
| Exact Mass |
318.25
|
| CAS # |
94513-92-5
|
| Related CAS # |
Nadolol;42200-33-9
|
| PubChem CID |
76973216
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
1.025
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
22
|
| Complexity |
344
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C(C([2H])([2H])[2H])(C([2H])([2H])[2H])NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O
|
| InChi Key |
VWPOSFSPZNDTMJ-GQALSZNTSA-N
|
| InChi Code |
InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/i1D3,2D3,3D3
|
| Chemical Name |
5-[3-[[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1401 mL | 15.7006 mL | 31.4011 mL | |
| 5 mM | 0.6280 mL | 3.1401 mL | 6.2802 mL | |
| 10 mM | 0.3140 mL | 1.5701 mL | 3.1401 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
